Adcentrx Therapeutics' ADRX-0706 Receives Fast Track Designation for Advanced Cervical Cancer

Adcentrx Therapeutics announced that the FDA granted Fast Track designation to its lead program, ADRX-0706, a Nectin-4 ADC, for treating locally advan...

Featured

Adcentrx Therapeutics' ADRX-0706 Receives Fast Track Designation for Advanced Cervical Cancer

Latest Regulatory Approvals Updates

Akeso's Ivonescimab Receives Breakthrough Therapy Designation in China for Triple-Negative Breast Cancer

Vizient Applauds FDA Actions to Accelerate Biosimilar Development and Lower Costs

FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) for Pulmonary Arterial Hypertension Based on Phase 3 ZENITH Study

FDA Approves Genentech's Gazyva for Lupus Nephritis Treatment

OS Therapies Receives FDA and MHRA Feedback on OST-HER2 for Metastatic Osteosarcoma

Civica to Launch Affordable Long-Acting Insulin Glargine in the US

Palisade Bio Receives Canadian Patent for PALI-2108 Composition

MannKind Announces FDA Acceptance of sBLA for Afrezza in Pediatric Diabetes Patients

Bicara Therapeutics Receives FDA Breakthrough Therapy Designation for Ficerafusp Alfa in 1L HPV-Negative R/M HNSCC

FDA Approves Boehringer Ingelheim's Jascayd (Nerandomilast) for Idiopathic Pulmonary Fibrosis

Spruce Biosciences Receives FDA Breakthrough Therapy Designation for Tralesinidase Alfa for Sanfilippo Syndrome Type B

Cellectar Biosciences Announces EMA Eligibility for Conditional Marketing Authorization of Iopofosine I 131 for Refractory Waldenstrom Macroglobulinemia

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for Cognitive Impairment Associated with Schizophrenia

Vanda Pharmaceuticals Announces Collaborative Framework with FDA for Dispute Resolution

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450

Kedrion Biopharma Receives FDA Approval for QIVIGY for Primary Humoral Immunodeficiency

Biogen Receives Complete Response Letter from FDA for High Dose Nusinersen in Spinal Muscular Atrophy

Noul Receives FDA Registration for Cervical Cancer Diagnostic Cartridge

Innovent's Mazdutide Approved in China for Glycemic Control in Type 2 Diabetes

Biocon Biologics Receives FDA Approval for Denosumab Biosimilars Bosaya and Aukelso

Saol Therapeutics Receives FDA Complete Response Letter for SL1009 (DCA) for Pyruvate Dehydrogenase Complex Deficiency

Agios Pharmaceuticals Announces PDUFA Date Extension for PYRUKYND® in Thalassemia

C4 Therapeutics' Partner Biogen Receives FDA IND Acceptance for IRAK4 Degrader BIIB142

Olomorasib Receives FDA Breakthrough Therapy Designation for KRAS G12C-Mutant Lung Cancer

FDA Accepts Waiver of Clinical Efficacy Studies for Monoclonal Antibody Biosimilars

FDA Approves BILDYOS® and BILPREVDA®, Biosimilars to PROLIA and XGEVA

Boehringer Ingelheim's HERNEXEOS® Approved in China for HER2-Mutant NSCLC

Abbott's Navitor TAVI System Receives CE Mark for Expanded Aortic Stenosis Indication

Vanda Pharmaceuticals' VGT-1849B Receives Orphan Drug Designation for Polycythemia Vera

Teva Launches First Generic GLP-1 for Weight Loss: Liraglutide Injection

Avenacy Launches Lidocaine Hydrochloride Injection in the U.S.

FDA Suspends License for Valneva's Chikungunya Vaccine IXCHIQ®

FDA Approves Wegovy® for the Treatment of MASH

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

AstraZeneca Launches At-Home Delivery Service for FluMist Nasal Spray Vaccine

FDA Approves Papzimeos for Recurrent Respiratory Papillomatosis

Echosens and Novo Nordisk Partner to Improve MASH Diagnosis and Treatment

Trinity Biotech Receives Regulatory Approval for PreClara™ Preeclampsia Test

FDA Clears DeepSight's NeedleVue™ LC1 Ultrasound System

Dyne Therapeutics' DYNE-251 Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy

Agios' PYRUKYND® (mitapivat) Approved for Thalassemia in Saudi Arabia

BioCardia Announces FDA and PMDA Regulatory Timeline for CardiAMP® Cell Therapy and Helix™ Catheter

AbbVie Seeks FDA Approval for Venetoclax and Acalabrutinib Combination in Untreated CLL

Sanofi's SAR446523 Receives Orphan Drug Designation for Multiple Myeloma

Positive CHMP Opinion for Deciphera's Vimseltinib in Treating Tenosynovial Giant Cell Tumor

Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment

Krystal Biotech's VYJUVEK® Approved in Japan for Dystrophic Epidermolysis Bullosa

Shanton Pharma's SAP-001 Receives FDA Fast Track Designation for Refractory Gout

Blenrep Combinations Approved in Canada for Relapsed/Refractory Multiple Myeloma

Protagonist Submits NDA for Icotrokinra, a Novel Oral Treatment for Plaque Psoriasis

Shorla Oncology's SH-110 Receives FDA Orphan Drug Designation for Glioma

ProKidney Announces FDA Alignment on Accelerated Approval Pathway for Rilparencel

Vertex Pharmaceuticals Wins Innovation Award for JOURNAVX™, a Novel Non-Opioid Acute Pain Treatment

Corcept Submits NDA for Relacorilant in Platinum-Resistant Ovarian Cancer

Caranx Medical Receives FDA Clearance for AI-Powered Software Guiding Transcatheter Heart Valve Implantation

Sun Pharma Launches LEQSELVI™ (deuruxolitinib) for Severe Alopecia Areata in the U.S.

FDA Grants Fast Track Designation to Zenith's ZEN-3694 for NUT Carcinoma

FDA Rejects Ultragenyx's Gene Therapy for Sanfilippo Syndrome Due to Manufacturing Issues

EMA Lifts Restriction on Valneva's Chikungunya Vaccine IXCHIQ® for Elderly Patients

Zevra Therapeutics Announces Presentations on MIPLYFFA® (arimoclomol) at Niemann-Pick Disease Conference

FDA Approves KERENDIA® (finerenone) for Heart Failure with LVEF ≥40%

FDA Grants Orphan Drug Designation to Klotho Neurosciences' KLTO-202 for ALS

Aktiia's Hilo Band: First Cuffless Blood Pressure Monitor Approved for OTC Use by FDA

FDA Approves Insightec's Exablate Neuro for Staged Bilateral Treatment of Parkinson's Disease

Novartis Receives Approval for First Malaria Medicine for Newborns and Young Infants

EmpNia Receives FDA Clearance for eMotus™ Respiratory Motion Management System

China Approves HUTCHMED's ORPATHYS® and TAGRISSO® Combination for Lung Cancer

FDA Grants Priority Review to Syndax's Revuforj® (revumenib) for Relapsed/Refractory mNPM1 AML

FDA Grants RMAT Designation to enGene's Detalimogene for High-Risk Bladder Cancer

Dupixent Approved for Bullous Pemphigoid

Zemcelpro® Receives Positive CHMP Opinion for Blood Cancer Treatment

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra) for MASH

Relief Therapeutics' RLF-TD011 Denied QIDP Designation but Remains on Track for EB Treatment

Ipsen's Cabometyx Receives Positive CHMP Opinion for Advanced Neuroendocrine Tumors

Dupixent Approved for Bullous Pemphigoid

FDA Approval of Keytruda for Head and Neck Cancer Highlights Potential for CEL-SCI's Multikine in PD-L1 Negative Patients

Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DYNE-101 in Myotonic Dystrophy Type 1